A common variant in CCDC93 protects against myocardial infarction and cardiovascular mortality by regulating endosomal trafficking of low-density lipoprotein receptor. (19th October 2019)

• Record Type: Journal Article
• Authors: Rimbert, Antoine; Dalila, Nawar; Wolters, Justina C; Huijkman, Nicolette; Smit, Marieke; Kloosterhuis, Niels; Riemsma, Marijn; van der Veen, Ydwine; Singla, Amika; van Dijk, Freerk; Frikke-Schmidt, Ruth; Burstein, Ezra; Tybjærg-Hansen, Anne; van de Sluis, Bart; Kuivenhoven, Jan Albert
• Is Part Of: European heart journal. Volume 41:Number 9(2020)
• Page Start: 1040
• Page End: 1053
• Publication Date: 2019-10-19
• Subjects: Low-density lipoprotein cholesterol -- Myocardial infarction -- Cardiovascular mortality -- LDL-receptor -- Endosomal trafficking -- CCDC93 -- CCC complex; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; 616.12005
• DOI: 10.1093/eurheartj/ehz727
• Languages: English
• ISSNs: 0195-668X

Abstract

Abstract: Aims: Genome-wide association studies have previously identified INSIG2 as a candidate gene for plasma low-density lipoprotein cholesterol (LDL-c). However, we suspect a role for CCDC93 in the same locus because of its involvement in the recycling of the LDL-receptor (LDLR). Methods and results: Characterization of the INSIG2 locus was followed by studies in over 107 000 individuals from the general population, the Copenhagen General Population Study and the Copenhagen City Heart Study, for associations of genetic variants with plasma lipids levels, with risk of myocardial infarction (MI) and with cardiovascular mortality. CCDC93 was furthermore studied in cells and mice. The lead variant of the INSIG2 locus (rs10490626) is not associated with changes in the expression of nearby genes but is a part of a genetic block, which excludes INSIG2 . This block includes a coding variant in CCDC93 p.Pro228Leu, which is in strong linkage disequilibrium with rs10490626 ( r 2 > 0.96). In the general population, separately and combined, CCDC93 p.Pro228Leu is dose-dependently associated with lower LDL-c ( P -trend 2.5 × 10 −6 to 8.0 × 10 −9 ), with lower risk of MI ( P -trend 0.04–0.002) and lower risk of cardiovascular mortality ( P -trend 0.005–0.004). These results were validated for LDL-c, risk of both coronary artery disease and MI in meta-analyses including from 194 000 to >700 000 participants. The variant is shown to increase CCDC93 protein stability, while overexpression of human CCDC93 decreases plasma LDL-c in mice. Conversely, CCDC93 ablation reduces LDL uptake as a result of reduced LDLR levels at the cell membrane. Conclusion : This study provides evidence that a common variant in CCDC93, encoding a protein involved in recycling of the LDLR, is associated with lower LDL-c levels, lower risk of MI and cardiovascular mortality.